Abstract
Quality assessment is a key issue in every clinical intervention, to be periodically performed so to measure the adherence to standard and to possibly implement strategies to improve its performance. This topic is rarely discussed for what concerns supportive care; however, it is necessary to verify the quality of the supportive measures; “supportive care makes excellent cancer care possible,” as stated by the Multinational Association of Supportive Care in Cancer (MASCC). In this regard, the quality of supportive care in head and neck cancer patients is a crucial topic, both to allow administration of treatments according to planned dose intensity or surgical indications and to maintain or improve patients' quality of life. This paper aims to provide insight on state of the art supportive care and its future developments for locally advanced and recurrent/metastatic head and neck cancer, with a focus on quality assessment in relation to surgery, radiotherapy, and systemic therapy.
Highlights
Quality assessment is a key issue in every clinical intervention, to be periodically performed so to measure the adherence to standard and to possibly implement strategies to improve its performance
This topic is rarely discussed for what concerns supportive care; it is necessary to verify the quality of the supportive measures; “supportive care makes excellent cancer care possible,” as stated by the Multinational Association of Supportive Care in Cancer (MASCC)
This paper aims to provide insight on state of the art supportive care and its future developments for locally advanced and recurrent/metastatic head and neck cancer, with a focus on quality assessment in relation to surgery, radiotherapy, and systemic therapy
Summary
Pierluigi Bonomo 1, Alberto Paderno 2, Davide Mattavelli 2, Sadamoto Zenda 3, Stefano Cavalieri 4 and Paolo Bossi 5,6*. The Keynote-048 clinical trial showed the efficacy of anti-PD1 (programmed death protein 1) pembrolizumab both as monotherapy and in addition to cisplatin-5-fluorouracil doublet [16]; supportive care should focus on the management of immune-related adverse events, such as endocrinopathies (e.g., hypothyroidism, hypophysitis), liver toxicity, and diarrhea. Given these premises, supportive care is of paramount importance along the whole disease trajectory of HNC: it entails all the pharmacological interventions and domainspecific processes aimed to prevent, manage, and mitigate the multifactorial burden of symptoms that may occur as a consequence of the disease and/or its treatments (Figure 1). This paper aims to provide insight on state of the art supportive care and its future developments for locally advanced and RM HNC, with a focus on quality assessment in relation to surgery, RT, and systemic therapy (Table 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
